# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-336717
Filing Date
2026-08-06
Accepted
2026-08-06 07:10:58
Documents
56
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | cgem-20260630.htm iXBRL | 10-Q | 1954529
2 | EX-31.1 | cgem-ex31_1.htm | EX-31.1 | 15719
3 | EX-31.2 | cgem-ex31_2.htm | EX-31.2 | 15495
4 | EX-32.1 | cgem-ex32_1.htm | EX-32.1 | 14531
| Complete submission text file | 0001193125-26-336717.txt |  | 8220325

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | cgem-20260630.xsd | EX-101.SCH | 1149495
60 | EXTRACTED XBRL INSTANCE DOCUMENT | cgem-20260630_htm.xml | XML | 1636174

Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39856 | Film No.: 261245948
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)